rBet v1-FV

BIOLOGICAL2 trials

Sponsors

Allergopharma GmbH & Co. KG

Conditions

Allergic Rhinoconjunctivitis

Phase 2

Immunological and Histological Evaluation of Specific Immunotherapy With Recombinant Hypoallergenic Derivative

CompletedNCT00841516

Allergopharma GmbH & Co. KGAllergic Rhinoconjunctivitis

Start: 2007-12-31End: 2013-05-31Updated: 2013-11-08

Dose Range Finding Study With rBet v1-FV - in Adult Patients With Birch Pollen-Allergic Seasonal Rhinoconjunctivitis

CompletedNCT01490411

Allergopharma GmbH & Co. KGAllergic Rhinoconjunctivitis

Start: 2010-10-31End: 2011-09-30Updated: 2014-01-24